Harbour BioMed

Harbour BioMed acquires Harbour Biomed Antibodies, plans to expand

Tuesday, December 20, 2016

Harbour BioMed, a recently established Shanghai-based company, has acquired Harbour Antibodies for cash and an equity interest in Harbour BioMed to create a new, global oncology-focused biotechnology company. The new company plans to leverage Harbour Antibodies’ patented transgenic mouse platforms to build an internal portfolio of next generation therapeutic antibodies for cancer, expand the range of partnerships and licenses around Harbour’s platforms, and capitalize on the Harbour BioMed management team’s extensive worldwide drug discovery and development expertise.

[Read More]